Quality of Life in Myeloablative Versus Nonmyeloblative Bone Marrow Transplant

在这项纵向研究中，我们前瞻性比较了接受非清髓性异基因外周血干细胞移植（A-PBSCT）和清髓性A-PBSCT患者的生活质量。 入组了78名18岁以上的受试者。 在移植前（基线）和移植后设定的时间间隔进行生活质量（医学结局研究简表-MOS SF-36和癌症治疗功能评估-一般和骨髓移植- FACT-G和FACT-G/BMT）和症状困扰（症状困扰量表- SDS）测量。 随着2002年的持续审查，该研究已停止接受新的应计费用。根据方案，入组的受试者在移植后2年内继续完成数据点。所有受试者均完成了其两年时间点，并于2004年底退出研究。因此，根据当时的方案审查标准，方案于2004年终止。2006年12月1日，IRB批准重新开放方案，仅用于数据分析（无新患者招募）。

In this longitudinal study we compared the QOL of patients undergoing a non-myeloablative allogeneic peripheral blood stem cell transplant (A-PBSCT) prospectively with that of a myeloablative A-PBSCT. Seventy-eight subjects over the age of 18 were enrolled. Measures of quality of life (Medical Outcomes Study Short Form-MOS SF-36 and Functional Assessment of Cancer Therapy-General and Bone Marrow Transplant - FACT-G and FACT-G/BMT) and symptom distress (Symptom Distress Scale - SDS) were administered prior to transplant (baseline) and at set interval post transplant. The study was closed to new accrual with the continuing review in 2002. Enrolled subjects continued to complete data points up to two years post transplant according to the protocol. All subjects completed their two year time point and were off study by the end of 2004. Therefore, the protocol was terminated in 2004 according to protocol review standards at that time. On 12/1/2006 the IRB approved re-opening of the protocol for data analysis (no new patient accrual) only.